Hoya Vision Care expands MiYOSMART spectacle lens power range to offer broader range of negative and cylindrical powers
The extension includes lenses that range from minus power of -13.00 diopters to cylindrical power up to 4.00 diopters
Apellis Pharmaceuticals receives Australian approval of pegcetacoplan (Syfovre) for treatment of geographic atrophy
The approval of Syfovre makes it the first and only approved treatment for GA in Australia.
Deafblind UK and Birmingham City University announce education and research centre
The centre will facilitate research and access to resources for the 450,000 residents of the UK who are affected by sight and hearing loss
MACUSTAR receives additional EMA support for AMD clinical study
The scientific outputs from MACUSTAR’s study could impact more than 200 million patients with AMD globally
HELIOS trial 1-year results assess implant for treatment of non-proliferative diabetic retinopathy
Diana V. Do, MD, spoke on behalf of the HELIOS investigators at the Hawaiian Eye and Retina 2025 Meeting, in Kauai, HI
Study describes ‘triangle sign’ as key to differentiating total choroidal detachments and suprachoroidal hemorrhages
Ultrasounds reveal the distinct feature within the vitreous anterior, a promising diagnostic indicator for ocular pathologies
Arctic Vision receives approval in Australia and Singapore for uveitic macular oedema treatment ARVN001
ARCATUS or ARVN001 was developed by Clearside Biomedical and commercialised in the Asia-Pacific region by Arctic Vision
NeurEYE research team leads AI-supported dementia detection programme with Scottish optometrists
Predictive software will use retinal imaging to identify patient risk for Alzheimer and other neurodegenerative diseases
Home storage of anti-VEGF agents presents risk of temperature changes
The study findings suggest that patients should be educated about adherence to cold storage guidelines
BLINK2 study results demonstrate myopia control outcomes following multifocal contact lens discontinuation
Participants wore high-add multifocal soft contact lenses for 2 years and single-vision lenses during the third year to determine if rebound occurred
iCare announces updated MAIA TrueColor Microperimetry System
The updated device is designed to meet market diagnostic needs, including within geographic atrophy research
Artificial intelligence supports screening more paediatric patients at lower cost
Autonomous, AI-based screening consistently resulted in more patients screened with greater cost savings, investigators said
Plant pathogen Macrophomina phaseolina may be emerging cause of ocular infection in humans
A case report highlights the pathogen’s potential to cause severe, devastating ocular infections, despite aggressive treatment
PulseSight Therapeutics submits Clinical Trial Authorisation for phase I trial of PST-611
The transferrin vectorised therapy is being investigated for use in patients with dry age-related macular degeneration and geographic atrophy
RhyGaze announces $86 million in Series A financing for optogenetic vision restoration therapy candidate
The company, which has European headquarters in Basel, Switzerland, plans to use the funds for a non-interventional, observational study and a first-in-human clinical trial
US FDA approves Zeiss MEL 90 excimer laser for myopia, hyperopia and mixed astigmatism
The laser integrates into the Corneal Refractive Workflow alongside the Visumax 800 and SMILE pro software
Teva partners with Klinge Biopharma, Lotus Pharmaceutical for commercialisation of Formycon’s FYB203 (biosimilar aflibercept)
The commercialisation agreements for the biosimilar to aflibercept (Eylea) cover Israel, major parts of Europe and the Asia-Pacific Region
Bausch + Lomb launches its enVista Aspire monofocal and toric intraocular lenses in the European Union
The launch follows a CE Mark received in late 2024
Study explores possible applications of retinal imaging in schizophrenia detection
The study built on previous research indicating specific retinal variables can serve as disease-related biomarkers in neurodegenerative diseases
Retinopathy of prematurity study demonstrates noninferiority of combination microdrops compared to standard mydriatics
The authors investigated systemic adverse events associated with commercial mydriatics administered during retinopathy of prematurity (ROP) screening
ViGeneron receives rare paediatric disease designation from US FDA for retinitis pigmentosa gene therapy candidate VG901
ViGeneron, based in Munich, also received approval for dose escalation in the ongoing phase 1b clinical trial
Conjunctival bacteria linked to higher fluoroquinolone resistance in new study from Brazil
Clinicians need to better understand how to reduce the growth of antibiotic-resistant, more virulent bacteria, the authors said
Oculis shares phase 2 ACUITY results for novel neuroprotective therapy OCS-05
Investigators reported that the trial demonstrated significant improvements in visual function and retinal structure for patients with optic neuritis
Regeneron acquires UK biotech company Oxular, broadening retina portfolio
In October, Oxular began a phase 2 trial for its therapeutic candidate OXU-001, for treatment of diabetic macular oedema
OCT and OCTA provide insights on neuroretinal changes associated with fibromyalgia
Patients with fibromyalgia experienced changes in the macular ganglion cell layer and retinal nerve fiber layer
International RESTORE study produces results of genetic therapy for Leber hereditary optic neuropathy
The RESTORE Study is the follow-up study of the RESCUE and REVERSE studies of lenadogene nolparvovec to treat vision loss from LHON
UK audit explores reasons patients skip diabetic retinopathy screenings
Investigators emphasised the need for continued efforts to raise awareness and support patients in attending regular screening
The year in review, with our friends from Modern Retina
Hot topics around the globe, from clinical trials to the solar eclipse
Ophthalmology Times wraps up a year of innovation and insight
Highlights from the year, courtesy of our colleagues at Ophthalmology Times
Looking back at 2024 with our colleagues from Optometry Times
The top therapeutic advancements in myopia, diabetes, dry eye and more
